Evidence map›Paper›PMID 41937236›Full record

ArticleBiotechnology progress

Rapid development of a transferable Raman model using high-throughput cell culture for monitoring monoclonal antibody titer.

Alexandra Umprecht, Nicholas Uth, Haenah Kim, Oliver Spadiut, Yang Yang

Abstract read
In one paragraph

Article in Biotechnology progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Spectroscopy-Based Cell Culture Predictive Monitoring.Biotech (Basel (Switzerland)) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Alexandra UmprechtPharmaceutical Sciences, R&D, Baxalta Innovations GmbH, a member of the Takeda group of companies, Vienna, Austria.ORCID 0009-0002-6380-3022
Nicholas UthPharmaceutical Sciences, R&D, Takeda Pharmaceutical Company Limited, Lexington, Massachusetts, USA.
Haenah KimPharmaceutical Sciences, R&D, Takeda Pharmaceutical Company Limited, Lexington, Massachusetts, USA.
Oliver SpadiutInstitute of Chemical, Environmental and Bioscience Engineering, TU Wien, Vienna, Austria.
Yang YangPharmaceutical Sciences, R&D, Takeda Pharmaceutical Company Limited, Lexington, Massachusetts, USA.

Funding

Takeda Pharmaceutical Company
6 · The paper itself

Abstract

Monoclonal antibody (mAb) titer monitoring is a key capability during process development and optimization, enabling timely decision making and increasing the speed of development. Raman spectroscopy is a prominent process analytical technology (PAT), but resource-efficient calibration strategies for the development of transferable models are limited. This work demonstrates the development and successful transfer of a calibration model for monoclonal antibody concentration between two different cell lines with varied metabolic profiles expressing different antibodies. The root mean square error of prediction (RMSEP) for titer in the source cell line (0.266 g L

Indexed as

Antibodies, MonoclonalCell Culture TechniquesHigh-Throughput Screening AssaysSpectrum Analysis, RamanAnimalsBioreactorsCalibrationCHO CellsCricetulusAntibodies, Monoclonalhigh‐throughput upstream developmentmodel transferabilityRaman spectroscopy

Identifiers

PMID41937236
PMCPMC13266923

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.